Recursion

Imagine you’re a researcher in a biotech startup, under pressure to fast-track drug discovery projects targeting aggressive cancers and rare diseases. Your small team is overwhelmed by the demands of collecting, analyzing, and interpreting vast amounts of biological data, and traditional methods have a high failure rate, threatening to derail your timeline. You’re searching for a solution that can help streamline these processes using advanced AI technology, promising better results and reduced costs. This is where an AI-driven platform like Recursion could potentially transform your workflow, offering a novel approach to drug discovery and development.

Recursion’s platform excels in harnessing AI for drug discovery by leveraging a large, proprietary dataset that includes over 50 petabytes of biological and chemical data. You can use this data to train machine learning models aimed at identifying new drug targets and designing optimized molecules. Although the website doesn’t specify the exact workflow, it highlights the use of robotics and computer vision to automate millions of cell experiments weekly. This enables your team to make novel discoveries faster, feeding results back into their Recursion Operating System for continuous improvement, ultimately aiming to lower the traditional drug discovery failure rate and improve efficiency.

Key Features

• Recursion Operating System — Integrates data and AI to improve drug discovery efficiency, crucial for reducing failure rates in traditional methods.
• BioHive-2 Supercomputer — Built with NVIDIA, it processes massive datasets quickly, assisting in faster drug development cycles.
• Automated Wet Lab — Uses robotics and computer vision to conduct millions of experiments, accelerating discovery timelines.

Pros & Cons

• ✓ Offers a massive proprietary dataset, enhancing the depth of analysis for drug discovery.
• ✓ Integrates AI and robotics for high-throughput experimentation, improving speed and efficiency.
• ✓ Partnerships with industry leaders to enhance capabilities and impact.

• ✗ Pricing is not disclosed on the website, potentially a barrier for smaller companies.
• ✗ The platform may not be suitable for non-pharmaceutical or non-biotech applications.

For a small biotech team, Recursion might not be the ideal fit. The tool focuses heavily on pharmaceutical applications and requires significant investment in proprietary datasets and AI training. If your team cannot access these resources or lacks the technical infrastructure to support the platform, this might limit your ability to fully capitalize on its capabilities. Additionally, the undisclosed pricing could be a deterrent for startups with limited budgets. In such scenarios, a more transparent or accessible tool might better suit your needs.

Comparing Recursion to other AI-driven drug discovery platforms like BenevolentAI or Atomwise, Recursion stands out with its significant investment in proprietary datasets and compute power, particularly its BioHive-2 supercomputer. However, if you’re a smaller team or a startup with budget constraints, Atomwise may be a more suitable choice due to its focus on small molecule discovery without the need for massive data resources. Meanwhile, BenevolentAI offers an option for those interested in deriving insights from literature and scientific data, which might appeal to research teams focused on knowledge extraction.

Best For

Recursion is ideal for mid-to-large pharmaceutical companies or research teams who can invest in advanced AI-driven research and development technology. Teams focusing on oncology or rare diseases will benefit from the platform’s ability to process vast datasets for accelerated drug discovery. Due to its undisclosed pricing, it’s better suited for teams with substantial budgets who are looking for innovative ways to improve drug discovery outcomes.

Recursion represents a strategic choice for pharmaceutical companies aiming to integrate AI into their drug discovery processes. It’s particularly valuable for organizations with the resources to leverage its expansive datasets and powerful computational infrastructure. Recursion is recommended for companies focused on oncology and rare diseases, seeking to reduce drug discovery failure rates and improve efficiency through AI.